Skip to main content

Posts

Showing posts from January, 2023

White Noise Sleep Aid Market Market Expected to Expand at a Steady 2023-2028

  White noise is a sound which is claimed to mask other sounds that occur naturally in the environment. White noise has the same amplitude throughout its audible frequency range of 20 to 20,000 hertz. It is analogous to white light, which consists of every visible wavelength on the color spectrum.  Global White Noise Sleep Aid Market: Dynamics The rising incidence of tinnitus and insomnia among adults is expected to drive the global white noise sleep aidmarket growth. For instance, according to data published in The Lancet Regional Health in January 2022, stated that the prevalence of any tinnitus was 14.7% in Europe, ranging from 8.7% in Ireland to 28.3% in Bulgaria. Severe tinnitus was found in 1.2% participants, ranging from 0.6% in Ireland to 4.2% in Romania between 2017-2018 Global White Noise Sleep Aid Market: Taxonomy By Power Source ·          Battery o     Rechargeable Batteries o     Non-rechargeable Batteries ·          Corded Electric By Indication Type

Treprostinil Drugs Market - High Prevalence of Pulmonary Arterial Hypertension and R&D of New Formulations of Treprostinil to Augment Growth of market

  Treprostinil is an antihypertensive agent used to treat patients with pulmonary arterial hypertension. It can also be used in the treatment of Degos disease, an extremely rare disorder in which small and medium sized arteries become blocked (occlusive arteriopathy), restricting the flow of blood to affected areas. Market Dynamics High prevalence of pulmonary arterial hypertension is expected to propel growth of the treprostinil drugs market . For instance, according to the study, ‘High Geographic Prevalence of Pulmonary Artery Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published in February 2020, in the journal Pulmonary Circulation, the overall pulmonary arterial hypertension incidence was 14 cases per million and the annual period prevalence of pulmonary arterial hypertension was 93 cases per million. Decline in new prescriptions for treprostinil-based products is expected to hinder growth of the treprostinil drugs market. For instance, United Therape